Attenua Inc., which as a virtual biotech gained oral neuronal nicotinic receptor (NNR) assets in development by Targacept Inc. prior to its 2015 merger with Catalyst Biosciences Inc., added some running room with a $35 million series A. The Mountain View, Calif.-based firm, which is advancing therapies to treat chronic cough, attracted an investor syndicate led by Omega Funds with participation from Abingworth, Orbimed and Redmile Group LLC.